Undisclosed HLA-A02 TP53-R175H targeting TCE / Affini-T Therap - LARVOL DELTA

Affini-T Therapeutics Presents Preclinical Data from its Programs Targeting Oncogenic Drivers KRAS and TP53 at AACR (Affini-T Press Release) - "Affini-T Therapeutics, Inc...today announced several presentations at this year’s American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago."

Clinical data • Preclinical • Solid Tumor